PARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer

By News Health
2 months Ago

(MedPage Today) — CHICAGO — Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received a PARP inhibitor in addition…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115861

Author :

Publish date : 2025-06-03 12:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

AI Detects Missed Interval Breast Cancer on Mammograms

We have detected a single electron with unprecedented speed

MHRA Approves First T1D Immunotherapy in UK

'The worst decision you could ever have to make'

Brain activity can predict whether strangers will become friends

Periods have 'massive impact' on female athletes